Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
Cytox Bolsters Support Through Stake By Masa Life Science Ventures
April 6, 2009
Birmingham, United Kingdom - Alzheimer's disease diagnostic developerCytox Ltd,has raised an undisclosed amount of funding through Masa Life Science Ventures in an ongoing fund-raising, VentureWire has learned.
Cytox Chief Executive and Director Richard Hadden declined to provide more details.
Cytox, founded in 2004, was initially incubated at and licensed its technology from the University of Oxford. The company's technology is designed to detect biomarkers associated with the cell division of brain cells to determine whether symptoms experienced by potential clinical-trial patients are symptoms of aging or early Alzheimer's disease.
Cytox raised this most recent funding around late last year or early this year, Hadden said. The company previously raised GBP1.2 million in 2006 including Birmingham, U.K.-based venture investor MidVen. MidVen is Cytox's largest investor, Hadden said, after investing GBP500,000. The company also has secured GBP400,000 in regional grant funding through Advantage West Midlands.
Separately, Masa founder and Managing Partner Sinclair Dunlop said his firm last summer added Director Kyp Sirinakis to fill a new position on the investment management team. Sirinakis previously was managing director at WomenAngels.net and director of the technology resource alliance at George Mason University Entrepreneurship Center.